We are live on ! Find out more

SCTX

Scribe Therapeutics Inc

SCTX

Market cap $625M

33.00 USD

+0.86

2.68%

At close Updated Sep 18, 4:00 PM EDT

Pre-market

After hours

33.00

0.00

0%

1 day

2.68%

5 days

10.11%

1 month

21.73%

3 months

52.42%

6 months

52.42%

Year to date

52.42%

1 year

52.42%

5 years

52.42%

10 years

52.42%

About: Scribe Therapeutics Inc is a clinical-stage biotechnology company engaged in the development of in vivo CRISPR-based genetic medicines. Its research and development activities focus on cardiovascular and metabolic diseases, including atherosclerotic cardiovascular disease (ASCVD). The company's product pipeline includes STX-1150, a CRISPR-based product candidate that utilizes its ELXR epigenetic silencing technology.

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 0%

Neutral 100%

Negative 0%

Scribe Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights

Initiated the first-in-human Phase 1 trial of STX-1150, a novel LDL-C lowering therapy powered by ELXR, a highly engineered epigenetic silencing technology designed to deliver ultra-long-acting cholesterol lowering without permanent genetic changes Awarded more than $25 million from the California Institute for Regenerative Medicine (CIRM) to advance both STX-1200 for Lp(a) lowering and STX-1400 for triglyceride lowering toward clinical entry Completed upsized initial public offering, including full exercise of the underwriters' purchase option, and a concurrent private placement to Sanofi, generating approximately $155.5 million in aggregate gross proceeds Cash, cash equivalents, and marketable securities of $43.0 million as of June 30, 2026, plus approximately $140.6 million of net proceeds raised from the July 2026 IPO and concurrent private placement, provides funding into the first half of 2029 ALAMEDA, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Scribe Therapeutics Inc. (“Scribe Therapeutics” or “the Company”) (Nasdaq: SCTX), a clinical-stage biotechnology company engineering purpose-built in vivo CRISPR technologies designed to extend healthy lifespan through disease prevention and durable therapeutic intervention, today reported financial results for the second quarter ended June 30, 2026, and provided recent corporate and pipeline updates.

Scribe Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights

Scribe Therapeutics to Participate in Upcoming Investor Conferences

ALAMEDA, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Scribe Therapeutics Inc. (“Scribe Therapeutics”) (Nasdaq: SCTX), a clinical-stage biotechnology company engineering purpose-built in vivo CRISPR technologies designed to extend healthy lifespan through disease prevention and durable therapeutic intervention, today announced that management will participate in the following upcoming investor conferences: Wells Fargo Healthcare Conference Boston, MASept.

Scribe Therapeutics to Participate in Upcoming Investor Conferences

Scribe Therapeutics Announces Closing of Initial Public Offering, Full Exercise of Underwriters' Option to Purchase Additional Shares, and Closing of the Concurrent Private Placement

ALAMEDA, Calif., July 27, 2026 (GLOBE NEWSWIRE) -- Scribe Therapeutics Inc. (“Scribe Therapeutics”) (Nasdaq: SCTX), a clinical-stage biotechnology company engineering purpose-built in vivo CRISPR technologies designed to extend healthy lifespan through disease prevention and durable therapeutic intervention, today announced the closing of its upsized initial public offering of 9,867,000 shares of its common stock, which includes the exercise in full by the underwriters of their option to purchase 1,287,000 additional shares, at the initial public offering price of $15.00 per share.

Scribe Therapeutics Announces Closing of Initial Public Offering, Full Exercise of Underwriters' Option to Purchase Additional Shares, and Closing of the Concurrent Private Placement

See News Rankings

Price charts implemented using Lightweight Charts™